What is Accretion Pharmaceuticals Ltd revenue growth outlook?

Accretion Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology sector and has a current market cap of ₹202 Cr and P/E ratio of 20.84. For detailed revenue growth insights derived from the latest earnings call, visit the Accretion Pharmaceuticals Ltd analysis page on Arthneeti AI.

What is Accretion Pharmaceuticals Ltd current stock price?

Accretion Pharmaceuticals Ltd current market price is ₹181. The stock trades at a P/E ratio of 20.84 with a market capitalisation of ₹202 Cr.

How does Arthneeti AI analyse Accretion Pharmaceuticals Ltd?

Arthneeti AI uses natural language processing to analyse Accretion Pharmaceuticals Ltd's earnings call transcripts and extract key insights on revenue growth, margins, capex plans, and fundraising activity. The analysis covers management commentary, forward guidance, and competitive positioning within the Pharmaceuticals & Biotechnology sector.

Accretion Pharmaceuticals Q4 FY26 Share Price & Earnings Call Analysis

₹181.00-2.16% today

Market cap: ₹202 Cr
P/E: 20.84
ROE: 27.63%
Price to sales: 2.26
Debt to equity: 0.23
52W high / low: ₹219 / ₹55.1
EBITDA margin: 16.70%
Net profit margin: 10.79%
Promoter holding: 73.52%
Sales (last year): ₹90 Cr

All 10 ratios ↓

Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]

Guidance scorecard · Q4 FY26 call

What Accretion Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#2of 83 in
Pharmaceuticals & Biotechnology

Revenue40%+MarginsUp 0–2%CapexPlanned FundraisingWhat management said Order bookRising

RevenueQ2 FY26 call

40%+

The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue.
Management indicated optimism for continued rapid sales growth in upcoming years, supported by a healthy order book and expanding export markets.
They anticipate leveraging newly added production capacity (with around a 40% capacity increase post-IPO), along with improved utilization and product mix, to drive volume growth.
FY '26 revenue is expected to surpass last year's INR57 crores significantly, aiming around INR120-130 crores based on current momentum.
The company plans to expand product registrations in new geographies (e.g., Rwanda, Nigeria, Cambodia) to bolster sales channels.

2 more points from Accretion Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Full Q2 FY26 analysis

MarginsQ2 FY26 call

Up 0–2%

Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.
The company anticipates EBITDA margins to improve from the current ~17% toward a steady-state of 20%-22%, as registration and scaling expenses normalize.
Profit after tax (PAT) is projected to grow significantly; with confidence expressed in maintaining or exceeding current profit levels (e.g., PAT closer to INR 10 crores anticipated).
Improved capacity utilization and expanded product registrations in multiple countries (e.g., Rwanda, Nigeria, Cambodia) will drive revenue and margin expansion.

2 more points from Accretion Pharmaceuticals Ltd's call on margins

Create a free account to keep reading this call

See what Accretion Pharmaceuticals Ltd said on margins — free account, 30 seconds.

Full Q2 FY26 analysis

CapexQ2 FY26 call

Planned

The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO.
The capex includes upgrading manufacturing facilities with new equipment to enhance capacity and compliance.
Future capex plans involve continued expansion and equipment upgradation to strengthen CDMO capabilities.
Focus on expanding product registrations and regulatory approvals in markets like Rwanda, Nigeria, Cambodia, and others to support growth.
Working capital has been augmented to support growing orders and ensure operational agility.

2 more points from Accretion Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Full Q2 FY26 analysis

FundraisingQ2 FY26 call

The company has recently completed a successful IPO in May 2025, raising INR29.75 crores.
Proceeds from the IPO have been strategically utilized for manufacturing facility upgrades, debt repayment, and working capital augmentation.
Short-term and long-term borrowings have drastically reduced due to loan repayments post-IPO.

2 more points from Accretion Pharmaceuticals Ltd's call on fundraising

Create a free account to keep reading this call

See what Accretion Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.

Full Q2 FY26 analysis

Order bookQ2 FY26 call

Rising

The company currently has a good order book, which supports their confidence in maintaining momentum in upcoming quarters.
They expect to sustain the growth rate seen in the first half of the year through efficient utilization of working capital and enhanced capacity.
New product launches and expansion into new countries also contribute to anticipated revenue growth from the order book.
The management confirms clarity on the existing order book and expects to deliver on these orders, contributing to PAT projections close to INR 10 crores for the year.

Full Q2 FY26 analysis

Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

This stockAccretion Pha.Strong growth
2
Strong growth
1
Strong growth
3

See all potential multibaggers All Pharmaceuticals & Biotechnology rankings

Portfolio builder

Build your portfolio
from the top-ranked stocks

1. Pick 3–15 stocks
2. Choose large, mid or small cap and your sectors
3. Get a portfolio built from the rankings

Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#	Company	Revenue guided	Margin guided	Market cap	P/E
1		40%+	Up 2%+	₹556 Cr	22.1
2	Accretion Pha.This stock	40%+	Up 0–2%	₹215 Cr	22.2
3		40%+	Flat	₹16,144 Cr	—
4		40%+	Flat	₹6,072 Cr	48.0
5		40%+	Flat	₹40 Cr	—
6		20–40%	Up 2%+	₹50,220 Cr	43.8

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Accretion Pharmaceuticals Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.